Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Phase separation of FUS is suppressed by its nuclear import receptor and arginine methylation.
Cell 173, 706-719.e13 (2018)
Purpose of Review Advances in technology have expanded telemedicine opportunities covering medical practice, research, and education. This is of particular importance in movement disorders (MDs), where the combination of disease progression, mobility limitations, and the sparse distribution of MD specialists increase the difficulty to access. In this review, we discuss the prospects, challenges, and strategies for telemedicine in MDs.Recent Findings Telemedicine for MDs has been mainly evaluated in Parkinson's disease (PD) and compared to in-office care is cost-effective with similar clinical care, despite the barriers to engagement. However, particular groups including pediatric patients, rare MDs, and the use of telemedicine in underserved areas need further research.Summary Interdisciplinary telemedicine and tele-education for MDs are feasible, provide similar care, and reduce travel costs and travel time compared to in-person visits. These benefits have been mainly demonstrated for PD but serve as a model for further validation in other movement disorders.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
31.398
5.008
229
294
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Als ; Ftd ; Karyopherin-β2 (kapβ2) ; Transportin (tnpo1) ; Arginine Methylation ; Fused In Sarcoma (fus) ; Neurodegeneration ; Nuclear Import ; Phase Separation ; Stress Granules; Randomized Controlled-trial; Chronic Tic Disorders; Parkinsons-disease; Health-care; Tourette-syndrome; Behavior-therapy; Neurological Disorders; Huntington Disease; Batten-disease; Virtual Visits
Sprache
Veröffentlichungsjahr
2018
HGF-Berichtsjahr
2018
ISSN (print) / ISBN
0092-8674
e-ISSN
1097-4172
Zeitschrift
Cell
Quellenangaben
Band: 173,
Heft: 3,
Seiten: 706-719.e13
Verlag
Cell Press
Verlagsort
Cambridge, Mass.
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Structural Biology (STB)
POF Topic(s)
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Enabling and Novel Technologies
PSP-Element(e)
G-503091-001
WOS ID
WOS:000430677400019
Scopus ID
85045120263
PubMed ID
29677514
Erfassungsdatum
2018-06-22